CHLVPP Chemotherapy in Advanced Hodgkin's Disease
Author Information
Author(s): J. McKendrick, J.M.A. Whitehouse, C.J. Williams, J. Sweetenham, D.H. Jones, G.M. Mead
Primary Institution: CRC Medical Oncology Unit, Southampton General Hospital
Conclusion
The CHLVPP chemotherapy regimen was generally well tolerated and resulted in a high rate of complete response among patients with advanced Hodgkin's disease.
Supporting Evidence
- Forty-two patients (77.8%) achieved complete response.
- Thirty-three patients (61.1%) were in continuous complete response at a mean follow-up of 44 months.
- Ten patients (18.5%) died during follow-up, with eight deaths attributed to Hodgkin's disease.
Takeaway
Doctors gave medicine to 54 people with a type of cancer, and most of them got better.
Methodology
Patients were treated with a combination of chlorambucil, vinblastine, procarbazine, and prednisolone at monthly intervals.
Limitations
The study had a relatively small sample size and a limited follow-up period.
Participant Demographics
The participants included 40 males and 14 females, aged 15 to 73 years, with a mean age of 29.
Want to read the original?
Access the complete publication on the publisher's website